Xencor Raises $15M

Monrovia, California-based Xencor said this morning that it has raised an additional $15M in its Series E round, bringing its total raised in the round to $60M. Xencor said the additional capital came from Oxford Bioscience Partners and Merlin Nexus, along with existing investor Novo Nordisk. The firm announced the first close of its Series E in October of last year. Xencor, which is developing pharmaceuticals for the treatment of Hodgkin's disease, T-cell lymphoma, and other cancers and inflammatory diseases, said the funding would go towards accelerating clinical validation and bring its candidates forward. The firm said RBC Capital Markets was a placement agent on the funding. The latest round of funding brings the company's total raised to at least $142M in funding. More information »